This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Bioterrorism  • Alert me on articles by topic  Social Bookmarking   What's this?

JAMA. 2001;286:2088-2090.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 20001;50:893-897

On September 11, 2001, following the terrorist incidents in New York City and Washington, D.C., CDC recommended heightened surveillance for any unusual disease occurrence or increased numbers of illnesses that might be associated with the terrorist attacks. Subsequently, cases of anthrax in Florida and New York City have demonstrated the risks associated with intentional release of biologic agents.¹ This report provides guidance for health-care providers and public health personnel about recognizing illnesses or patterns of illness that might be associated with intentional release of biologic agents.

Health-Care Providers

Health-care providers should be alert to illness patterns and diagnostic clues that might indicate an unusual infectious disease outbreak associated with intentional release of a biologic agent and should report any clusters or findings to their local or state health department. The covert release of a biologic agent may not have an immediate impact because of the delay between exposure . . . [Full Text of this Article]

Anthrax

Plague

Botulism

Smallpox (variola)

Inhalational tularemia

Hemorrhagic fever (such as would be caused by Ebola or Marburg viruses)

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?